APDM Instrumented Data Exchange for Ataxia (IDEA) Study

Status: Completed
Location: See all (5) locations...
Study Type: Observational
SUMMARY

This research study is testing body-worn sensors to measure movement during simple tests of coordination, in order to evaluate the progression and severity of ataxia.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 75
Healthy Volunteers: t
View:

• SCA 1, 2, 3, 6, and FA with mutations in the pathogenic range confirmed from genetic testing

• SCA: aged 18-75 years

• FA: aged 12-30, diagnosed between ages 5-25

• community dwelling

• physically/cognitively capable of consenting/assenting and complying with the protocol based on investigator's judgement

• able to walk independently 10 yards without an assistive device

• able to sit or stand unassisted for 30 seconds

• no other neurological or musculoskeletal disorder that could affect mobility

• no other history of head injury, vestibular function, stroke, or other disorders that could affect mobility

• willing and able to participate in a 2-year study

• consent to be video recorded while performing study assessments

Locations
United States
California
University of California-Los Angeles
Los Angeles
Illinois
The University of Chicago
Chicago
Massachusetts
Mass General Hospital
Boston
Maryland
Johns Hopkins Medicine
Baltimore
Oregon
Oregon Health & Science University
Portland
Time Frame
Start Date: 2019-06-01
Completion Date: 2024-06-30
Participants
Target number of participants: 128
Treatments
Spinocerebellar Ataxia-1
individuals with a genetically confirmed diagnosis of SCA-1
Spinocerebellar Ataxia-2
individuals with a genetically confirmed diagnosis of SCA-2
Spinocerebellar Ataxia-3
individuals with a genetically confirmed diagnosis of SCA-3
Spinocerebellar Ataxia-6
individuals with a genetically confirmed diagnosis of SCA-6
Freidreich's Ataxia
individuals with a genetically confirmed diagnosis of FA
FA Controls
Healthy, age-matched controls
SCA Controls
Healthy, age-matched controls
Sponsors
Collaborators: Pfizer, APDM Wearable Technologies, Biogen
Leads: University of Chicago

This content was sourced from clinicaltrials.gov